These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16549979)

  • 1. Defining clinically relevant HIV drug resistance--from drug development to clinical reality.
    Miller V
    AIDS; 2006 Apr; 20(6):929-31. PubMed ID: 16549979
    [No Abstract]   [Full Text] [Related]  

  • 2. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration.
    Dalmau D; Klimkait T; Telenti A
    Antivir Ther; 2005; 10(7):867-72. PubMed ID: 16312184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Resistance development. Are drug resistant HIV-1 minorities relevant for therapeutic success?].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():15. PubMed ID: 19024909
    [No Abstract]   [Full Text] [Related]  

  • 4. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    Zolopa AR
    J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 drug resistance in variants from the female genital tract and plasma.
    Kemal KS; Burger H; Mayers D; Anastos K; Foley B; Kitchen C; Huggins P; Schroeder T; Picchio G; Back S; Gao W; Meyer WA; Weiser B
    J Infect Dis; 2007 Feb; 195(4):535-45. PubMed ID: 17230413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV drug resistance tests: an update on methods for calculating phenotypic fold change from a viral genotype.
    Bellosillo NA; Bacheler L; Villacian J
    Clin Infect Dis; 2009 Mar; 48(5):687; author reply 687. PubMed ID: 19191661
    [No Abstract]   [Full Text] [Related]  

  • 7. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment: resistance testing--an integral part of HIV management.
    Katzenstein DA
    AIDS Read; 2003 Jan; 13(1):36. PubMed ID: 12569893
    [No Abstract]   [Full Text] [Related]  

  • 9. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.
    Vermeiren H; Van Craenenbroeck E; Alen P; Bacheler L; Picchio G; Lecocq P;
    J Virol Methods; 2007 Oct; 145(1):47-55. PubMed ID: 17574687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update of the Drug Resistance Mutations in HIV-1.
    Johnson VA; Brun-Vezinet F; Clotet B; Gunthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD
    Top HIV Med; 2008 Dec; 16(5):138-45. PubMed ID: 19106428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Algorithms for the interpretation of HIV-1 genotypic drug resistance information.
    Vercauteren J; Vandamme AM
    Antiviral Res; 2006 Sep; 71(2-3):335-42. PubMed ID: 16782210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on the drug resistance situation among recently infected HIV-1 patients in Dehong].
    Wang MJ; Duan S; Xiang LF; Yang YC; Tu YQ; Wang JB; Yao J; Qi J; Jiang Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Sep; 29(9):905-8. PubMed ID: 19173856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients.
    Flandre P; Costagliola D
    AIDS; 2006 Oct; 20(16):2118-20. PubMed ID: 17053360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
    Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
    J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of HIV-1 pol diversity on drug resistance and its clinical implications.
    Kantor R
    Curr Opin Infect Dis; 2006 Dec; 19(6):594-606. PubMed ID: 17075337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of primary genotypic resistance in a UK centre: Comparison of primary HIV-1 and newly diagnosed treatment-naive individuals.
    Fox J; Hill S; Kaye S; Dustan S; McClure M; Fidler S; Mackie NE
    AIDS; 2007 Jan; 21(2):237-9. PubMed ID: 17197816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical devices: immunology and microbiology devices: classification of in vitro human immunodeficiency virus drug resistance genotype assay. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Aug; 72(152):44380-2. PubMed ID: 17687800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to HIV integrase inhibitors.
    Winslow DL
    AIDS Alert; 2011 Sep; 26(9):106-7. PubMed ID: 22003537
    [No Abstract]   [Full Text] [Related]  

  • 20. Understanding transmitted HIV resistance through the experience in the USA.
    Taiwo B
    Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.